The year 2019 marked a major turnaround for Silence, as it both ramped up its development activity, with the advancement of SLN124 for iron overload and SLN360 for cardiovascular disease, and made massive partnering efforts. We have seen the fruits of this business development in the form of three partnering deals with major pharmaceutical companies Mallinckrodt, Takeda and AstraZeneca. Together all these efforts demonstrate the value of the company’s siRNA platform and intellectual pro
16 Apr 2020
Silence Therapeutics - A year of unprecedented change
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Silence Therapeutics - A year of unprecedented change
Silence Therapeutics plc (SLNCF:OTC) | 0 0 0.0%
- Published:
16 Apr 2020 -
Author:
Dr Nathaniel Calloway -
Pages:
5
The year 2019 marked a major turnaround for Silence, as it both ramped up its development activity, with the advancement of SLN124 for iron overload and SLN360 for cardiovascular disease, and made massive partnering efforts. We have seen the fruits of this business development in the form of three partnering deals with major pharmaceutical companies Mallinckrodt, Takeda and AstraZeneca. Together all these efforts demonstrate the value of the company’s siRNA platform and intellectual pro